Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEND001 in Idiopathic Pulmonary Fibrosis
NCT05657184Phase 1Completed
- Sponsor
- Regend Therapeutics
- Start
- Jul 2021
- Primary completion
- Jun 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bronchial basal cells in idiopathic pulmonary fibrosis (IPF), sponsored by Regend Therapeutics. Primary endpoint: Incidence and severity of cell therapy-related adverse events at 24 weeks. Started Jul 2021; status: completed.
02
Drugs
autologous bronchial basal cells
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05657184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05657184.